- US-listed companies
- Ascendis Pharma A
- Income statement
Ascendis Pharma A (ASND) Income statement
Market cap
P/E ratio
| 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 2 | 11 | 13 | 7 | 8 | 51 | 267 | 364 |
| Revenue growth (%) | - | |||||||
| Gross profit | - | - | - | - | 4 | 39 | 222 | 319 |
| Gross margin (%) | - | - | - | - | ||||
| Research & development | 100 | 140 | 192 | 261 | 296 | 380 | 413 | 307 |
| Selling, general & administrative | 13 | 25 | 48 | 77 | 160 | 221 | 264 | 291 |
| Operating margin (%) | ||||||||
| Operating income | -112 | -155 | -227 | -331 | -452 | -562 | -456 | -279 |
| Income before tax | -124 | -130 | -218 | -419 | -384 | -578 | -474 | -373 |
| Pretax margin (%) | -8,129 | -1,233.3 | -1,631.8 | -6,028.7 | -4,936.3 | -1,129.1 | -177.8 | -102.6 |
| Net income | -124 | -130 | -218 | -419 | -384 | -583 | -481 | -378 |
| Net income margin (%) |